Tag Archives: CNS

Business, Finance, Occupation & Industry

NTRR Seeks Out Alternative Cannabinoid Treatments for Pain Management

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

NTRR Seeks Out Alternative Cannabinoid Treatments for Pain Management

SARASOTA, Fla.–(BUSINESS WIRE)– As part of its initiative to market and develop healthier, more effective alternatives to smoking for medical marijuana patients, Neutra Corp. (OTCBB: NTRR) is currently exploring cutting-edge, alternative cannabinoid treatments for those who need it most: patients who suffer from chronic pain.

Recent studies have suggested that cannabis-derived treatments can be safe and effective in the treatment of neuropathic pain, rheumatoid arthritis and cancer pain—three notoriously difficult ailments to alleviate. Additionally, injections of synthetic cannabinoids have shown great promise in enhancing morphine’s antinociceptive effect while preventing the buildup of tolerance to the drug in patients.

With pain affecting 1.5 billion people worldwide, drugs and analgesics to treat it comprise one of the major segments of the central nervous system (CNS) therapies market. NTRR believes that cannabinoid treatments could hold the key to unlocking a whole new era of pain management, helping the company to break into the $52 billion pain management market. NTRR is seeking out potential partners who are developing breakthrough delivery systems capable of helping patients cope with chronic pain in new, more effective ways.

The company is dedicated to commercializing innovative, all-natural products to compete in the fast-growing medical marijuana sector alongside Cannabis Science Inc. (PINK: CBIS), Medical Marijuana Inc. (PINK: MJNA), HEMP Inc. (PINK: HEMP) and Growlife Inc. (PINK: PHOT).

For more information on NTRR‘s initiatives, please visit www.neutracorp.com/investors.html.

Follow NTRR on Twitter at www.twitter.com/neutracorp.

About Neutra Corp.

Neutra Corp. (www.neutracorp.com) is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products and services as well as protective, anti-microbial coatings for indoor and outdoor surfaces. For investing information and performance data, please visit www.neutracorp.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or

From: http://www.dailyfinance.com/2013/04/18/ntrr-seeks-out-alternative-cannabinoid-treatments-/

Business, Finance, Occupation & Industry

Teva to Report First Quarter 2013 Financial Results on May 2, 2013

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Teva to Report First Quarter 2013 Financial Results on May 2, 2013

JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYS: TEVA) announced today that it will release its first quarter 2013 financial results on Thursday, May 2, 2013 at 7:00 a.m. ET.

Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2013 results and overall business environment. A Question & Answer session will follow this discussion.

In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 1-888-771-4371; International 1-847-585-4405; passcode: 34657214.

A live webcast of the call will also be available on Teva’s website at: www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company’s website. The replay can also be accessed until May 9, 2013, at 11:59 p.m. ET by calling 1-888-843-7419 or 1-630-652-3042; passcode: 34657214.


About Teva

Teva Pharmaceutical Industries Ltd. (NYS: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

Teva Pharmaceutical Industries Ltd.
IR:
Kevin C. Mannix
United States
215-591-8912
or
Kristen Frank
United States
215-591-8908
or
Tomer Amitai
Israel
972 (3) 926-7656
or
PR:
Hadar Vismunski-Weinberg
Israel
972 (3) 926-7687
or
Denise Bradley
United States
215-591-8974

KEYWORDS:   Middle East  Israel

INDUSTRY KEYWORDS:

The …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neuro

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting

LATE-BREAKING ORAL PRESENTATION PLANNED FOR AZILECT ® (RASAGILINE TABLETS)

JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYS: TEVA) today announced that 15 abstracts highlighting study results for Parkinson’s disease (PD) and relapsing-remitting multiple sclerosis (RRMS) will be presented during the 65th American Academy of Neurology (AAN) annual meeting in San Diego, Calif., March 16-23, 2013. New data for AZILECT® (rasagiline tablets), an MAO-B inhibitor for the treatment of PD, will be presented as part of the meeting’s Emerging Science program (formerly known as Late-Breaking Science) on Wednesday, March 20th at 5:45pm PST.

“We are pleased with the variety of topics and quality of research results that will be presented at AAN this year,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. “Teva’s legacy in CNS is grounded in our commitment to ongoing collaboration with academia, medical institutions, and patient advocacy groups to find innovative solutions for patients who live with chronic and debilitating diseases, such as RRMS and Parkinson’s disease.”

Featured presentations include:

  • Results from a Phase IV clinical study evaluating AZILECT® as Add on to Dopamine Agonists in the Treatment of Parkinson’s disease (ANDANTE).
  • Findings from the first year of follow-up in the Therapy Optimization in Multiple Sclerosis (TOP MS) study, the largest prospective Phase IV study conducted in RRMS, providing insight into the impact of adherence to therapy, as well as data demonstrating that more patients on COPAXONE® (glatiramer acetate) persisted with treatment than those on beta interferon (IFN).
  • Results from the Phase III ALLEGRO study in RRMS at 36 months, comparing the progression of disability and safety of patients treated with laquinimod for three years (Early-Start) and in patients originally treated with placebo in the double-blind (DB) phase and switched to laquinimod treatment (Delayed-Start) in the open-label (OL) phase of the ALLEGRO trial.

Platform Presentation/Poster Session Details:


AZILECT
 ®

Business, Finance, Occupation & Industry

Teva Files 2012 Annual Report on Form 20-F

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Teva Files 2012 Annual Report on Form 20-F

JERUSALEM–(BUSINESS WIRE)– In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYS: TEVA) announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company’s complete audited financial statements, free of charge. Requests can be made by contacting Teva Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by phone at (215) 591-8912 or 011-972-3-926-7656.

About Teva

Teva Pharmaceutical Industries Ltd. (NYS: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
Kristen Frank, 215-591-8908
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Hadar Vismunski-Weinberg, 972 (3) 926-7687
or
United States
Denise Bradley, 215-591-8974

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:

The article Teva Files 2012 Annual Report on Form 20-F originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
…read more
Source: FULL ARTICLE at DailyFinance